Vir Biotechnology (VIR) Net Margin (2018 - 2026)
Vir Biotechnology recorded quarterly Net Margin of 433431.03% in Q1 2026, down 646870.77% quarter-over-quarter from 66.99% in Q4 2025, and down 42944142.0% year-over-year from N/an in Q1 2025.
Vir Biotechnology's Net Margin history runs 9 years deep, the most recent figure standing at 433431.03% for Q1 2026.
- In Q1 2026, Net Margin fell 42944142.0% year-over-year to 433431.03%; the TTM figure through Mar 2026 stood at 675.36% (up 209368.0% YoY), while the FY2025 annual figure was 638.87%, up 6453.0% from the prior year.
- Net Margin came in at 433431.03% for Q1 2026 at Vir Biotechnology, down from 66.99% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 46.81% in Q3 2022 to a low of 433431.03% in Q1 2026.
- A 5-year average of 31858.58% and a median of 845.23% in 2024 frame the typical range for Net Margin.
- Across the five-year window, Net Margin surged 859021 bps in 2022 and slumped 42944142 bps in 2026, its largest moves.
- Vir Biotechnology's Net Margin stood at 205.63% in 2022, then tumbled by 236 bps to 690.85% in 2023, then fell by 22 bps to 845.23% in 2024, then surged by 92 bps to 66.99% in 2025, then slumped by 646871 bps to 433431.03% in 2026.
- According to Business Quant data, Net Margin over the past three periods registered 433431.03%, 66.99%, and 67975.42% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 0.82% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 34.53% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 20.17% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 17.65% |
| 10 | Vir Biotechnology | 1.33 Bn | 1.33 Bn | - | -433,431.03% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -433,431.03% |
| Dec 31, 2025 | -66.99% |
| Sep 30, 2025 | -67,975.42% |
| Jun 30, 2025 | -9,139.87% |
| Mar 31, 2025 | -3,989.61% |
| Dec 31, 2024 | -845.23% |
| Sep 30, 2024 | -8,979.71% |
| Jun 30, 2024 | -4,500.10% |
| Mar 31, 2024 | -126.26% |
| Dec 31, 2023 | -690.85% |
| Sep 30, 2023 | -6,192.23% |
| Jun 30, 2023 | -5,129.71% |
| Mar 31, 2023 | -223.80% |
| Dec 31, 2022 | -205.63% |
| Sep 30, 2022 | 46.81% |
| Jun 30, 2022 | -188.27% |
| Mar 31, 2022 | 42.08% |
| Dec 31, 2021 | 64.63% |
| Sep 30, 2021 | 106.57% |
| Jun 30, 2021 | 36.73% |
| Mar 31, 2021 | -8,548.13% |
| Dec 31, 2020 | -6,732.12% |
| Sep 30, 2020 | -4,388.43% |
| Jun 30, 2020 | -71.98% |
| Mar 31, 2020 | -1,350.82% |
| Dec 31, 2019 | -6,507.24% |
| Sep 30, 2019 | -3,443.62% |
| Jun 30, 2019 | -1,657.45% |
| Mar 31, 2019 | -783.12% |
| Dec 31, 2018 | -844.31% |
| Sep 30, 2018 | -1,159.65% |